New pill combo aims to control CLL without lifelong treatment

NCT ID NCT07508995

Not yet recruiting Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing two oral drugs, BGB-16673 and sonrotoclax, in 40 people with untreated chronic lymphocytic leukemia (CLL). The goal is to see if this combination can safely control the disease for a limited time, potentially reducing the need for ongoing therapy. Participants will take the drugs by mouth and be monitored for side effects and how well the cancer responds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BGB-16673 and sonrotoclax (oral drugs)
What this could lead to: If successful, this could offer a new, time-limited treatment option for people with untreated CLL, potentially controlling the disease without lifelong therapy.
What could go wrong: This is an early phase 2 trial with only 40 participants, so results may not apply to everyone. The combination could cause side effects or fail to work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Contacts and locations

Locations

UT MD Anderson

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.